Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients
Authors:
- 1 May 2002
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 99 (9) , 3163-3168
Abstract
The role of maintenance therapy in multiple myeloma is controversial. Recent studies have shown an improvement in both progression-free and overall survival for patients receiving maintenance treatment with a combination of interferon and glucocorticoids, compared with interferon alone. The role of glucocorticoids alone as maintenance therapy has not been previously addressed. We compared alternate-day, oral prednisone at 2 different dose levels (10 mg versus 50 mg) for remission maintenance among previously untreated myeloma patients following a response to induction with standard-dose vincristine, doxorubicin, and dexamethasone with prednisone (VAD-P) or VAD-P plus quinine (VAD-P/Q). There were 250 eligible patients registered on Southwest Oncology Group study 9210 and randomized to receive VAD-P or VAD-P/Q. There were 125 patients achieving at least a 25% tumor reduction following induction therapy who were randomized to either physiologic (10 mg) or pharmacologic (50 mg) doses of alternate-day, oral prednisone until disease progression. At the time of study entry, patient characteristics were similar in VAD-P and VAD-P/Q patients and in the 2 arms randomized to maintenance therapy. After a median follow-up of 53 months, there was no difference in either progression-free or overall survival between the 2 induction regimens. However, from the time of maintenance randomization, both progression-free (14 versus 5 months; P = .003) and overall survival (37 versus 26 months; P = .05) were significantly improved in patients receiving 50 mg as compared with 10 mg alternate-day prednisone. There was no difference in treatment-related adverse events between the groups. Thus, 50 mg, oral, alternate-day prednisone is effective maintenance treatment for multiple myeloma patients who achieve a response to induction chemotherapy.Keywords
This publication has 34 references indexed in Scilit:
- A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment GroupEuropean Journal of Cancer, 1995
- Interferon plus Glucocorticoids as Intensified Maintenance Therapy Prolongs Tumor Control in Relapsed MyelomaActa Haematologica, 1993
- High‐dose dexamethasone for refractory or relapsing multiple myelomaAmerican Journal of Hematology, 1991
- Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction ChemotherapyNew England Journal of Medicine, 1990
- VAD‐based regimens as primary treatment for multiple myelomaAmerican Journal of Hematology, 1990
- Complete remission in multiple myelomaThe Lancet, 1990
- INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMAThe Lancet, 1989
- Dose Intensity Analysis of Melphalan and Prednisone in Multiple MyelomaJNCI: Journal of the National Cancer Institute, 1988
- Response rate and survival in myeloma patients receiving prednisone aloneMedical and Pediatric Oncology, 1985
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958